Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare Population

Completed

Conditions studied: Chronic Myeloid Leukemia (CML)

In brief

The purpose of this study is to examine the healthcare costs among patients with CML receiving dasatinib or nilotinib as first line therapy in a commercially or Medicare insured population.

Key facts

Study ID

NCT02363868

Run by

Bristol-Myers Squibb

People needed

186

Starts

2014-02-01

Expected to finish

2014-11-01

Last updated by the study team

2015-07-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age >18 years
• International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9 CM) code for CML (205.1x)
• At least 2 prescriptions for dasatinib or nilotinib from July 1, 2008 to June 31, 2013
• Continuous eligibility for the 6 months pre- and post-index date (defined as the date of first fill for dasatinib or nilotinib)

You may not qualify if…

• History of bone marrow or stem cell transplant as identified in the 6 month pre-period

Where it is running

• Franklin Pharmaceutical Consulting, Llc — Clinton, South Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.